References
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10(5):589–95.
- Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 2013;123(6):400–8.
- Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7(40):iii, ix–x, 1–111.
- Bavikatte G, Gaber T. Approach to spasticity in general practice. Brit J Med Pract 2009;2(3):29–34.
- Nicholas R, Chataway J. Multiple sclerosis. Clin Evid (Online) 2009;5:44–54.
- Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;(4):CD001332.
- Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 2012;5(5):255–66.
- Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42(8):495–503.
- Sativex Oromucosal Spray, Summary of Product Characteristics. July 2011.
- Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16(6):707–14.
- Collin C, Davies P, Mutiboko IK, Ratcliffe S. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14(3):290–6.
- Collin C, Ehler E, Waberzinek G, A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32(5):451–9.
- Novotna A, Mares J, Ratcliffe S, Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9): 1122–31.
- García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013;13(3 Suppl. 1):1–5.
- Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30(5):974–85.
- Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev Neurother 2013;13(3 Suppl. 1):1–5.
- Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260(1):285–95.